Preview

Онкоурология

Расширенный поиск

АДЪЮВАНТНАЯ ЛУЧЕВАЯ ТЕРАПИЯ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ

https://doi.org/10.17650/1726-9776-2010-6-1-65-69

Полный текст:

Аннотация

The rate of a biochemical and clinical recurrence at stage T1-T2 is 25-35%. Experience with surgical treatment for stage T3 cancer shows that 33.5-66% of patients a positive surgical margin and 7.9-49% of patients have a metastatic lymph node lesion. One of the further treatment options is teleradiotherapy (TRT) for a removed prostate area, which is performed immediately after surgical treatment and in case of a biochemical or clinical recurrence both alone and in combination with others treatments (hormonal therapy, chemotherapy, etc.). The paper presents the data of basic international studies of adjuvant radiotherapy after radical prostatectomy. The results of the therapy depend on the baseline level of prostate-specific antigen, the interval between the start of radiotherapy and surgery, the stage of the disease, and other prognostic factors. A number of investigations of the use of TRT, hormonal therapy, chemotherapy, and their combinations in the adjuvant mode are ongoing. This will provide answers to what combinations of adjuvant therapy may increase survival and improve quality of life in patients with prostate cancer.

Об авторе

А. О. Карякин
МРНЦ РАМН, Обнинск
Россия


Список литературы

1. Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095-101.

2. Joniau S., Hsu C.Y., Lerut E. et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2):388-96.

3. Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95(6):751-6.

4. Hsu C.Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007;51(1):121-8; discussion 128-9.

5. Русаков И.Г., Алексеев Б.Я. Адъю-вантная терапия после радикальной простатэктомии. Материалы междуна-родной научно-практической конфе-ренции Актуальные вопросы диагно-стики и лечения рака предстательной железы. М., 2006. с. 78-87.

6. Клиническая онкоурология. Под ред.Б.П. Матвеева. М., 2003. с.538-9.

7. Han M., Partin A.W., Pound C.R. et al. Long-term biochemical disease-free and cancerspecific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3)555-65.

8. Rosser C.J., Chichakli R., Levy L.B. et al. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 2002;168(2):536-41.

9. Horwitz E.M., Thames H.D., Kuban D.A. et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005;173(3):797-802.

10. Taylor J.A. III, Koff S.G.,Dauser D.A., McLeod D.G. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 2006;98(3):540-3.

11. Stephenson A.J., Kattan M.W.,Eastham J.A. et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24(24):3973-8.

12. Boccon-Gibod L., Djavan W.B.,Hammerer P. et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382-90.

13. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163(6):1632-42.

14. Stamey Т.А., Kabalin J.N.,McNeal J.E. et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141(5):1076-83.

15. Partin A.W., Pearson J.D., Landis P.K. et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43(5):649-59.

16. Trapasso J.G., de Kernion J.B.,Smith R.B., Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-5.

17. Клинические рекомендации. Онко-урологические заболевания. EAU, РООУб 2009; раздел 14.5. с. 122.

18. Grossfeld G.D., Stier D.M.,Flanders S.C. et al. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 1998;1609(4):1398-404.

19. Lu-Yao G.L., Potosky A.L.,Albertsen P.C. et al. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996;88(3-4):166-73.

20. Fowler F.J. Jr., Barry M.J.,Lu-Yao G.L. et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42(6):622-9.

21. Bott S.R.J. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004;7(3):211-6.

22. Polascik T.J., Oesterling J.E.,Partin A.W. Prostate specific antigen: a decade of discovery -what we have learned and where we are going. J Urol 1999;162(2):293-306.

23. Wu J.J., King S.C., Montana G.S. et al. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;32(2):317-23.

24. Schild S.E., Buskirk S.J., Wong W.W. et al. The use of radiotherapy or patients with isolated elevation of prostate specific antigen following radical prostatectomy. J Urol 1996;156(5):1725-9.

25. Forman J.D., Meetze K., Pontes E. et al. Therapeutic irradiation for patients with an elevated postprostatectomy prostate specific antigen level. J Urol 1997;158(4):1436-9; discussion 1439-40.

26. Nudell D.M., Grossfeld G.D.,Weinberg V.K. et al. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54(6):1049-57.

27. Carroll P. Rising PSA after a radical treatment. Eur Urol 2001;40(Suppl 2):9-16.

28. Cadeddu J.A., Partin A.W.,DeWeese T.L., Walsh P.C. Long-term results of radiation therapy forprostate cancer recurrence following radical prostatectomy. J Urol 1998;159(1):173-7; discussion 177-8.

29. Haab F., Meulemans A.,Boccon-Gibbod L. et al. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 1995;45(6):1022-7.

30. Egewa S., Matsumoto K., Suyama K. et al. Limited suppression of prostate specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 1999;53(1):148-55.

31. Vicini F.A., Ziaja E.L., Kestin L.L. et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999;54(1):111-7.

32. Cox J.D., Gallagher M.J.,Hammond E.H. et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17(4):1155-63.

33. MacDonald O.K., Schild S.E., Vora S. et al. Salvage radiotherapy for men with isolated rising PSA or local palpable recurrence after radical prostatectomy: do outcomes differ? Urology 2004;64(4):760-4.

34. Swanson G.P., Hussey M.A.,Tangen C.M. et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007;25(16):222-9.

35. Stephenson A.J., Scardino P.T.,Kattan M.W. et al. Predicting outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035-41.

36. Hanks G.E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr 1988;(7):75-84.

37. Kupelian P.A., Katcher J., Levin H.S.,Klein E.A. Staging Tl-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37(5):1043-52.

38. Bolla M., van Poppel H.,van Cangh P.J. et al. Acute and late toxicity of post operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911. Int J Rad Oncol Biol Phys 2002;54(Suppl 2):62. Abstr 103.

39. Van Cangh P.J., Richard F., Lorge F. et al. Adjuvant therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol 1998;159(1):164-6.

40. Swanson G.P., Thompson I.M.,Tangen C. et al. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Rad Oncol Biol Phys 2008;72:31.

41. Spahn M., Joniau S., Gontero P. et al. The role of adjuvant treatment strategies after surgery for high-risk localized prostate cancer. Eur Urol Suppl 2009. Abstr 521.

42. Briganti A., Gallina A., Suardi N. et al. Patients with pT2 prostate cancer and positive surgical margins do not benefit from adjuvant radiation therapy. Eur Urol Suppl 2009. Abstr 746.

43. Briganti A., Karnes J.R., Da Pozzo L.F. et al. Adjuvant radiotherapy has a positive impact on cancer-specific survival of lymph node positive prostate cancer patients. Results of a matched analysis of a two-institution series with 703 lymph node positive patients. Eur Urol Suppl 2009. Abstr 46.

44. Wilder R.B., Hsiang J.Y., Ji M. et al. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level post-prostatectomy. Am J Clin Oncol 2000;23(2):176-80.

45. Track B.J., Han M., Freedland S.J. et al. Prostate cancerspecific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-9.


Для цитирования:


Карякин А.О. АДЪЮВАНТНАЯ ЛУЧЕВАЯ ТЕРАПИЯ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ. Онкоурология. 2010;6(1):65-69. https://doi.org/10.17650/1726-9776-2010-6-1-65-69

For citation:


Karyakin O.В. ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Cancer Urology. 2010;6(1):65-69. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-1-65-69

Просмотров: 446


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X